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Abstract
This work aimed to synthesize a novel β-cyclodextrin derivative, itaconyl-β-cyclodextrin to evaluate whether albendazole
inclusion complexes with the new β-cyclodextrin derivative-improved albendazole dissolution efficiency and its anthelminthic
activity. The new derivative was thoroughly evaluated and characterized, and an average degree of substitution of 1.4 per
cyclodextrinmolecule was observed. Albendazole:itaconyl-β-cyclodextrin complexes were prepared by spray drying procedures
and investigated using phase solubility diagrams, dissolution efficiency, X-ray diffraction, differential scanning calorimetry,
Fourier transform infrared, scanning electronic microscopy, mass spectrometry, and nuclear magnetic resonance spectroscopy.
Phase solubility diagrams and mass spectrometry studies showed that the inclusion complex was formed in an equimolar ratio.
Stability constant values were 602 M−1 in water, and 149 M−1 in HCl 0.1 N. Nuclear magnetic resonance experiments of the
inclusion complex showed correlation signals between the aromatic and propyl protons of albendazole and the itaconyl-β-
cyclodextrin inner protons. The studies indicated solid structure changes of albendazole included in itaconyl-β-cyclodextrin.
The maximum drug release was reached at 15 min, and the inclusion complex solubility was 88-fold higher than that of the pure
drug. The in vitro anthelmintic activity assay showed that the complex was significantly more effective than pure albendazole.
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Introduction
Strategies for enhancing dissolution of poorly water-soluble
drugs can be classified mainly into two groups: chemical and
physical. One of the chemical strategies involves the modifi-
cation of the molecule by incorporating functional groups to
increase drug hydrophilicity or to induce ionization in the
gastrointestinal fluids [1]. Physical strategies include to mod-
ify drug solid state; particle size reduction; optimize the solu-
bilization process employing co-solvents and surfactants.
These all physical strategies are relatively simple procedures
to achieve an improvement in biopharmaceutical properties.
Special attention needs to be paid to metastable polymorphs,
salts, co-crystals, and amorphous forms that tend to
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recrystallize into their most stable form. The reduction of par-
ticle size presents the risk of agglomeration and crystal
growth. Dosage forms using surfactants and lipids are highly
versatile, but they require extensive characterizations and can
be related to the following risks: toxicity of the excipients,
drug precipitation, and modification of the pharmacokinetic
profile and biodistribution [2].
Another significant physical strategy to improve the solubility
of poorly soluble compounds is the preparation of inclusion
complexes with cyclodextrins (CDs). CDs have been studied
for over 100 years, yet they are still considered novel pharma-
ceutical excipients [3]. They have been gaining interest in the
past years, alongside the rise of a variety of substituted CDs.
Besides an enhanced solubility, drug inclusion complexes can
lead to improve drug availability, and drug stability by preventing
degradation. CDs are a family of cyclic oligosaccharides that
possess biological properties similar to those of their linear coun-
terparts [3, 4]. The three most widely used CDs (α,β, and γ) are
crystalline, homogeneous, and non-hygroscopic excipients [5].
The fact that oligomeric CDmolecules are formed by six to eight
glucopyranose units bound via α-1,4 glycosidic linkages pro-
vides this group of supramolecular compounds with remarkable
advantages. The CD molecule can be conceived as a truncated
conewith a hydrophilic exterior. The cone inner walls are formed
by the hydrophobic carbon backbones of the glucopyranose
units, generating a hydrophobic interior. This particular structure
supports the use of CDs as solubilizers of poorly water-soluble
chemicals [6–8].
Nevertheless,β-CD shows considerably low solubility in wa-
ter and this issue can be overcome by chemical modification
obtaining randomly substituted heterogeneous products, non
crystallizable, useful for the pharmaceutical industry [4]. CD
crystallinity is thought to be due to relatively strong intermolec-
ular hydrogen bonding in the crystalline state. Substitution of any
of the hydrogen bonds forming hydroxyl groups results in nota-
ble improvement in its aqueous solubility [9, 10]. CD derivatives
of pharmaceutical interest include the hydroxypropyl derivatives
of β and γ-CD, the randomly methylated-β-CD,
sulfobutylether-β-CD, citrate-β-CD, succinyl-β-CD, and the
branched CDs such as glucosyl-β-CD [7, 9–11].
Since CDs can form water-soluble inclusion complexes
with many poorly soluble lipophilic drugs, they are used to
enhance the drug aqueous solubility and to improve its bio-
availability after oral administration [12, 13]. The formation of
complexes with CDs is one of the several strategies employed
to increase solubility, dissolution rate and oral bioavailability
of such poorly water-soluble drugs [9, 11, 14, 15].
Albendazole (ABZ), a benzimidazole carbamate, is an an-
thelmintic compound showing larvicide, ovicide, and vermi-
cide activity. It is widely used in the treatment of trichinellosis,
a parasitic disease caused by the helminth Trichinella spp. [11,
13]. Its effectiveness is limited by its poor water solubility
(1 μg/mL at 25 °C) and the consequent low bioavailability,
producing in some cases an unpredictable therapeutic
response.
The synthesis of a novel CD derivative, itaconyl-β-CD
(I-β-CD), to optimize the oral administration of poorly soluble
compounds, mainly those with basic characteristics such as
ABZ, is an attractive matter to improve the current anthelmin-
tic therapeutic alternatives. Indeed, inclusion complexes for-
mation is markedly improved by the interaction when the CD
and the drug have opposite charges [12, 16].
The characterization of I-β-CD and its inclusion com-
plexes is fundamental to understand the host-guest molecule
interaction. Different experiments of nuclear magnetic reso-
nance (NMR) spectroscopy and mass spectrometry have been
used to characterize them [9, 10].
Thus, this paper describes a simple and interesting method
to synthesize a novel CD derivative and its application on
ABZ complexation, as well as the complete physicochemical
characterization of the derivative and its complexes using dif-
ferent techniques. Additionally, the in vitro anthelminthic ac-
tivity of the formulations was evaluated on Trichinella spiralis
(T. spiralis) adult parasites.
Materials and methods
Materials
ABZ, NaH2PO2.H2O, and itaconic acid (IA) were purchased
from Sigma-Aldrich (Chemie GmbH, Steinheim, Germany),
and β -CD was dona t ed by Roque t t e (F rance ) .
Hydroxypropyl-β-CD (HP-β-CD) and methyl-β-CD (M-β-
CD) were purchased from Sigma-Aldrich (Chemie GmbH,
Steinheim, Germany). Absolute ethanol was obtained from
Laboratorio Cicarelli (Argentina). RPMI 1640 medium was
purchased from Gibco Laboratories (USA), fetal bovine se-
rum from Natocor (Argentina), and gentamicin from Klonal
(Argentina). All other chemicals used were of analytical re-
agent grade.
Methods
Synthesis of I-β-CD
The synthesis of I-β-CD was carried out by reflux heating. IA
(8.12 mmol, 1.056 g) was dissolved in distilled water
(0.8 mL), then NaH2PO2.H2O (0.58 mmol, 62.5 mg) and β-
CD (1.16 mmol, 1.316 g) were added. Molar ratio between β-
CD and IAwas 1:7. The mixture was heated at 120 °C for 5 h.
After that, 20 mL of absolute ethanol were added to separate
the desired product by precipitation. The precipitate was fil-
tered and washed until the pH of the supernatant was neutral,
which indicates that there was no free IA remaining. Finally,
the reaction product (I-β-CD) was dried 24 h at 60 °C [17].
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Characterization of I-β-CD
The yield of the β-CD derivative was calculated by the rela-
tionship between the moles of I-β-CD and the moles of
starting β-CD.
Solution NMR spectra, 1D 1H, 13C and 1H-1H TOCSY, 2D
1H-1H COSY, 1H-13C HSQC, and 1H-13C HMBC, were re-
corded on a Bruker Avance 300 MHz NMR spectrometer
(Karlsruhe, Germany). Samples of I-β-CD were prepared in
D2O (24 mM) (δ 4.7 ppm).
The mass spectrum was performed on a Bruker
micrOTOF-Q II mass spectrometer (Bruker-Daltonics,
Bremen, Germany). The analysis conditions were as follows:
ESI negative mode, scan 200–2000 m/z, nebulizer pressure
0.4 bar, temperature 180 °C, drying gas flow rate 4.0 L/min,
capillary voltage 4500 V, and collision energy 35 eV.
I-β-CD molecular weight and degree of substitution (DS)
were calculated from NMR and mass spectrometry studies [9,
10].
DS was determined from 1H NMR spectrum by using Eq.
1:
DS ¼ AH−b’ þ AH−b*
2 x AH−1ð Þ ð1Þ
where AH-1 is the H-1 proton peak area, while AH-b* and AH-b’
correspond to the vinyl proton peak areas.
Besides, DS was calculated according to Eq. 2, assuming
that the spectrometer has the same sensitivity for CDs with
different DS.
DS ¼
∑
i
i DSi
∑
i
I i
ð2Þ
where Ii and DSi denote the intensity and the DS of peak ith,
respectively.
Preparation and characterization of ABZ:I-β-CD systems
Phase solubility diagrams The phase solubility assay was car-
ried out as follows. An excess of ABZ (~ 25mg) was added to
vials containing 5 mL of increasing concentration solutions,
from 0 to 50mM (0, 65.0, 129.9, 194.9, 259.8, and 324.8 mg),
of I-β-CD in 0.1 NHCl (pH 1.2) or bidistilled water. Solutions
were stirred (200 rpm) for 72 h at 25 °C. Afterward, solutions
were filtered through a 0.45-μm pore size syringe filter and
ABZ c o n c e n t r a t i o n w a s d e t e rm i n e d b y UV-
spectrophotometry at 292 nm. The complex formation con-
stant (Kf) was calculated from the slope (S) and intercept (So)
of the phase solubility diagram, according to Eq. 3 reported by
Higuchi and Connors: [5, 18].
K f ¼ S=So 1−Sð Þ ð3Þ
The same procedure was repeated employing β-CD,
HP-β-CD, and M-β-CD to compare the Kf values.
Preparation of ABZ:I-β-CD systems The inclusion complex
was prepared in a molar ratio of 1:1 (ABZ:I-β-CD). ABZ
(0.565 mmol, 150 mg) was solubilized in 10 mL of glacial
acetic acid and I-β-CD (0.565 mmol, 734.4 mg) in 20 mL of
water. Both solutions were mixed under stirring and immedi-
ately dried in a Mini Büchi Spray Dryer B-290 (Flawil,
Switzerland) at 130 °C with a feed rate of 5 mL/min [19, 20].
In addition, a physical mixture of ABZ and I-β-CD was
prepared for comparison, by mixing both compounds in a
mortar for 10 min.
Yield and ABZ content of spray dried complex The complex
yield was calculated according to the following equation:
Yield %ð Þ ¼ Wproduct
WABZ þWI−β−CD  100 ð4Þ
whereWproduct is the weight of the product obtained after spray
drying, WABZ and WI-β-CD are the weights of raw materials
ABZ and I-β-CD, respectively.
The determination of the ABZ content was carried out by
UV spectrophotometry. Briefly, a sample of 20.0-mg complex
was dissolved in a 100-mL volumetric flask with 0.1 M HCl.
ABZ concentration solution was determined at 292 nm and
the ABZ content of spray dried complex was calculated as
percentage (w/w).
Characterization of the ABZ:I-β-CD systems The morphology
of ABZ, I-β-CD, ABZ:I-β-CD physical mixture (PM), and
inclusion complex powders by spray drying (SD) was studied
through images by scanning electronic microscopy (SEM) on
a Leitz AMR 1600 T, with an accelerating potential of 20 kV.
Samples were previously distributed on an aluminum support
and gold sputter-coated to make them conductive.
Differential scanning calorimetry (DSC) measurements
were conducted on a Shimadzu TA-60 calorimeter (Kyoto,
Japan). Each sample was placed in a crimped aluminum pan
and scanned from 25 to 300 °C at a rate of 5 °C/min, under a
nitrogen flow of 30 mL/min. Calibration was performed with
indium and zinc as standards [20, 21].
An automated X’Pert Philips 5000 diffractometer
(Eindhoven, The Netherlands) was used for X-Ray diffraction
(XRD) analysis, in reflexion mode at room temperature.
Diffraction data were obtained using Cu-Kα radiation (k =
1.54056 Å), applying 40 kV and 20 mA, with a step size of
2θ = 0.02° [22].
Fourier transform infrared (FT-IR) spectra of the samples
were recorded using KBr disk method on an FT-IR-Prestige-
21 Shimadzu spectrometer (Tokyo, Japan). Scanning range
was 450–3900 cm−1 with a resolution of 1 cm−1.
Drug Deliv. and Transl. Res. (2019) 9:273–283 275
1H, 13C, 1H-1H COSY, 1H-13C HSQC, 1H-13C HMBC, and
ROESY experiments were carried out on a Bruker Avance
300 MHz NMR spectrometer (Karlsruhe, Germany).
ABZ:I-β-CD complex (10 mg) was dissolved in 0.1 N DCl.
ROESY spectra were acquired with 32 scans, an acquisition
time of 0.222 s and a relaxation delay of 2 s.
The stoichiometry of the complex was confirmed by mass
spectrometry on a micrOTOF-Q II spectrometer (Bruker-
Daltonics, Germany). ABZ:I-β-CD complex (1 mg) was dis-
solved in formic acid (1 mL, 0.4% v/v), and was diluted 1/100
with a methanol:water mixture (50:50). The analysis condi-
tions were as follows: ESI method, negative mode, collision
energy − 10 eV, nebulizer 0.4 bar, temperature 180 °C, flow
rate of the drying gas 4.0 L/min, and m/z range 50–3000.
Apparent solubility Solubility assays were conducted by
adding an excess amount of the PM or the inclusion complex
prepared by SD in vials with 10 mL of distilled water. The
vials were sealed and stirred for 72 h at 200 rpm. Afterward,
solutions were filtered using 0.45-μm syringe filters and ABZ
concentrations were obtained by UV-spectrophotometry at
292 nm. All determinations were done in triplicate.
Additionally, apparent solubility assays of ABZ:β-CDs sys-
tems were carried out to make a comparison with commercial-
ly available CDs (β-CD, HP-β-CD, and M-β-CD).
Dissolution studies The dissolution studies were performed
using the paddle method (USP apparatus II Hanson
Research SR8 Plus, Chatsworth, USA), according to the
USP XXXII [23]. Samples containing 100 mg of ABZ were
added into dissolution vessels with 900 mL of HCl 0.1 N at
37.0 ± 0.1 °C; the temperature was maintained within that
range during the whole process. Solution aliquots (5mL) were
collected at different times to determine drug release spectro-
photometrically [24].
Additionally, dissolution efficiency (DE) of ABZ powder,
PM, and inclusion complex (SD) was calculated applying Eq.
5.
DE %ð Þ ¼ ∫
t
0y dt
y100  t
 100 ð5Þ
where ∫t0y dt is the area under the dissolution curve in an
interval of time t, and y100 × t is the rectangle area considering
100% dissolution at the same interval.
Dissolution studies of complexes with commercial CDs
(β-CD, HP-β-CD, and M-β-CD) obtained by PM and SD
were performed to compare them with the new derivative.
In vitro evaluation of the anthelmintic activity of the ABZ-I-β-
CD systems on Trichinella spiralis adult parasites T. spiralis
female worms were obtained from a donor mouse during the
intestinal phase of the infection, on day 6 post-infection, as
already described [25, 26].
ABZ, I-β-CD, ABZ:I-β-CD (PM), and ABZ:I-β-CD (SD)
stock solutions were prepared in DMSO and were added to
RPMI 1640 medium supplemented with 250 μg/mL of gen-
tamicin, to obtain working solutions with a final concentration
of 500 μg ABZ/mL. Each working solution was prepared,
stirred for 24 h at 150 rpm and 25 °C and filtered through a
0.22-μm sterile cellulose acetate filter, before use.
The in vitro assay was done under sterile conditions. T.
spiralis female worms were incubated overnight in the
RPMI 1640 medium supplemented with gentamicin
(250 μg/mL) and fetal bovine serum (10% v/v), at 37 °C, in
a 5% CO2 atmosphere, before being used. The antiparasitic
activity assay was done in a 24-well plate, placing 1.8 mL of
the working solutions, 200 μL fetal bovine serum and 10 to 12
females in each well. The ABZ solution was used as a positive
control and the culture mediumwith the solvent employed as a
negative control. Plates were incubated in a humid 5% CO2
atmosphere at 37 °C for 48 h and were observed under an
inverted microscope at 2, 4, 6, 24, 30, and 48 h to count the
dead worms. Parasites viability was estimated analyzing their
motility and morphology, and they were classified into two
categories: (0) dead; (1) alive, with normal morphology and
varying degrees of motility [27]. The ABZ solution was used
as the positive control and the culture medium with DMSO as
the negative control. The assay was made in triplicate. Data
were corrected by the negative control median at each time
point. The efficacy of the different antiparasitic treatments was
assessed by analyzing parasite survival with the Kaplan-Meier
survival curve, which defines the probability of surviving in a
given length of time while considering time in many small
intervals; each time point represents the median percentage
of live parasites.
T. spiralis female fertility was also evaluated by the number
of newborn larvae (NL) per well at each time point. Fertility
was scored as follows: (0) no NL in the well, (+) 1 to 30 NL,
and (++) more than 30 NL.
Statistical analysis
Apparent solubility values and DE values between ABZ:β-
CDs systems were analyzed. One-way ANOVA tests were
used followed by Tukey’s multiple comparison tests. As
regards in vitro experiments, survival curves were calculated
with the product limit method of Kaplan and Meier.
Comparison of the survival curves was done with the log-
rank test.
GraphPad Prism 7.00 (GraphPad Software, Inc., San
Diego, CA) was used to calculate all statistics. P values <
0.05 were considered significant.
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Results and discussion
Characterization of I-β-CD
The I-β-CD derivative was obtained with a yield of 71%. A
complete characterization by NMR analysis was carried out to
determine the I-β-CD derivative substitution pattern. The as-
signment of the 1H and 13C peaks are exhibited in the hori-
zontal and vertical projections of the HSQC spectrum, respec-
tively (Fig. 1). 1H-13C HSQC spectrum showed a 1H signal at
δ 3.34 ppm that was correlated with a13C signal at δ
37.90 ppm; these signals correspond to methylene groups of
the itaconyl substituent (a and a’, Fig. 1).
Two peaks were observed in the 1H NMR spectrum at 4.45
and 4.18 ppm which presented cross-peaks with the 13C peak
at 64.38 ppm on the multiplicity-edited HSQC spectrum.
These signals correspond to the substituted nuclei at position
6 (X6sub). A downfield shift in these signals position with
respect to those produced by the non-substituted homologous
nuclei resulted from the deshielding of the nucleus by the
substituent. The presence of signals corresponding to
unsubstituted nuclei at position 6 indicates a partial substitu-
tion of the I-β-CD. The average DS could be quantified from
the proton peak areas. As shown in Fig. 1, H-b’ and H-b* did
not overlap, thus DS could be determined by comparing the
sum of these two peaks (which integrated two protons) to the
peak area of H1 (which integrated one proton). DS obtained
from 1H NMR was 1.40 per CD molecule. The DS analysis
was carried out over three batches and the relative standard
deviation (variation coefficient) obtained for this parameter
was 4.2%, indicating a high reproducibility in the synthesis
of this derivative.
The I-β-CD mass spectrum (Fig. 2), performed in negative
ionization mode, shows the ions with m/z ratios of 1245.4,
1357.4, and 1469.4, which correspond to I-β-CD molecules
with one, two, or three substituents, respectively. These ions
had a clearly asymmetric distribution; the peak with greater
intensity was due to the derivative with one substituent. The
DS calculated by Eq. 2 was 1.52, which was consistent with
that obtained by NMR.
Characterization of the ABZ:I-β-CD systems
Yield, ABZ content, and solubility studies
The spray drying technique allowed to obtain the ABZ:I-β-
CD inclusion complex with a yield of 80% and an ABZ con-
tent of 17.2% (w/w). This value was in agreement with the
molar ratios between both compounds (1:1) and their molec-
ular weights.
The phase solubility diagrams of ABZ inclusion complex
(I-β-CD) in water and HCl (Fig. 3a) showed a linear relation-
ship between ABZ and the CD derivative. Similarly, the phase
solubility diagrams carried out in water, (ABZ:β-CD,
ABZ:HP-β-CD, ABZ:M-β-CD, and ABZ:I-β-CD) showed
a linear relationship between ABZ and the CDs, fitting an
AL-type system (Fig. 3b). This type of curves indicates the
formation of soluble 1∶1 type inclusion complex.
The Kf value obtained for the inclusion complex between
ABZ and I-β-CD was 602 M−1, denoting a relatively more
stable complex in comparison with those obtained with tradi-
tional CDs (β-CD, 74 M−1; HP-β-CD, 313 M−1; and M-β-
CD, 337 M−1). This greater stability of the ABZ:I-β-CD in-
clusion complex could be explained by interaction charges
Fig. 1 I-β-CD HSQC spectrum
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between the carboxylic groups of the derivative and the amino
groups of ABZ.
The Kf values for ABZ:I-β-CD system were 602 M
−1 in
water and 149 M−1 in HCl 0.1 N. As expected, ABZ intrinsic
solubility (S0) was higher at acidic pH. However, this im-
provement of solubility obtained at acidic pH reduced the
stability of the complex. A lower Kf value could be attributed
to the lower affinity of the positively charged ABZ for the
hydrophobic I-β-CD cavity. After administering the complex
orally, ABZ would be easily released from the I-β-CD cavity
into the stomach, facilitating its absorption.
SEM micrographs
Figure 4 shows micrographs of ABZ, I-β-CD, and ABZ:I-β-
CD systems obtained by SD and PM. ABZ particles (Fig. 4a)
had an irregular form and were larger than 10 μm in diameter.
I-β-CD solid particles presented spherical shape and smooth
and variable surface. The PM system micrograph allows to
clearly visualize ABZ and I-β-CD maintaining their original
structure and size. On the contrary, the finding of predomi-
nantly spherical particles (Fig. 4d) suggests the formation of a
new structure in the solid state between ABZ and I-β-CD in
the SD system [28].
XRD diffractograms
The ABZ XRD diffractogram (Fig. 5a) showed intense and
sharp peaks at 2θ 11.51; 17.85; 22.09, and 24.54, indicating
that this compound was in a crystalline state. Contrariwise, the
broad peaks observed in the I-β-CD diffractogram signified
that it was in an amorphous state. The XRD pattern of the
ABZ:I-β-CD system obtained by PM showed the characteris-
tic peaks of ABZ (2θ 11.51, 17.85, 22.09, and 24.54) as well
as those of I-β-CD. Conversely, the diffractogram from the
ABZ:I-β-CD system obtained by SD only showed the signals
at 2θ 17.85 and 24.54 corresponding to ABZ, but with a lower
intensity than those of the diffractogram from the system ob-
tained by PM. These results suggest a change in the solid
structure of the inclusion complex in comparison with the
starting materials [29, 30].
DSC thermograms
ABZ, I-β-CD, and both ABZ:I-β-CD systems DSC thermo-
grams (Fig. 6) were performed to evaluate whether changes in
the ABZ melting peak occurred when combined with I-β-CD
andwhether the preparationmethod influenced those changes.
The characteristic melting peak of ABZ appeared at
196.84 °C. This peak was also observed in the PM thermo-
gram and, though present, it was less intense in the thermo-
gram of the system prepared by SD. This could be due to a
modification in the crystallinity of the drug loaded in the last
system. These results agreed with those obtained by XRD
analysis [28].
FT-IR analysis
Figure 7 shows the results of the FT-IR analysis. ABZ FT-IR
spectrum presented the characteristic transmittance bands at
3332 cm−1 (N–H stretching vibration), 2954 and 2927 cm−1
(CH3/CH2 groups), 2661 cm
−1 (vibrations of the C-H links),
1712 cm−1 (amide band), 1632 cm−1 (stretching vibration of
the aromatic rings), 1589 cm−1 (stretching vibration of
Fig. 2 I-β-CD mass spectrum
Fig. 3 Phase solubility diagrams.
Concentration of ABZ against
increasing concentrations of I-β-
CD, in water or in HCl 0.1 N (a).
Comparison of I-β-CD and com-
mercial CDs in water (b)
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aromatic C–N bonds), and 1523 cm−1 (amide band). I-β-CD
FT-IR spectrum showed wide bands with a transmittance peak
at 3385 cm−1 corresponding to the symmetric and asymmetric
stretching vibration of the −OH groups, and another band at
2929 cm−1 related to the stretching vibration of the C–H
bonds. The transmittance peaks at 1157 cm−1 and 1028 cm−1
were due to the asymmetric and symmetric stretching vibra-
tion corresponding to the C–O–C bonds. On the other hand,
the peak at 1734 cm−1 marked the ester bond formed between
the carboxylic groups of IA and the hydroxyls of β-CD.
The FT-IR spectra from the systems showed absorption
bands corresponding to both I-β-CD and ABZ. There were
no remarkable differences between the two spectra, except for
the absorption bands at 3332 cm−1 (found superimposed with
that originated by the OH groups of the CD) and 2954 cm−1
(corresponding to ABZ), observed only in the spectrum of the
PM. These results indicated structural differences produced by
the SD process in the ABZ:I-β-CD system. [31, 32]
ROESY NMR experiments
ROESYNMR experiments are relevant to determine inter and
intramolecular interactions. Closely located protons can
produce a nuclear Overhauser effect (NOE) cross-correlation
in ROESY; the presence of NOE cross-peaks indicates spatial
contacts within 0.4 nm between two species.
ABZ and I-β-CD proton labels, and the ROESY spectrum
from the ABZ:I-β-CD system obtained by SD are shown in
Fig. 8. In this spectrum, the I-β-CD internal protons (H3, H5,
H6) presented cross-peaks with the aromatic protons of ABZ (e:
Fig. 5 XRD diffractograms. ABZ (a), I-β-CD (b), ABZ:I-β-CD (PM)
(c), and ABZ:I-β-CD (SD) (d)
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Fig. 4 SEM micrographs. ABZ (a), I-β-CD (b), ABZ:I-β-CD (PM) (c), and ABZ:I-β-CD (SD) (d)
δ = 7.24 ppm, f: δ = 7.37 ppm, and g: δ = 7.40 ppm). These
protons also showed signals of correlation with protons a, b, and
c of ABZ, the correlation with protons b being weak (a: δ =
0.80 ppm, b: δ = 1.40 ppm and c: δ = 2.79 ppm, Fig. 7).
The ROESY spectrum allowed us to conclude that both the
aromatic ring and the tail of ABZ are inside the CD derivative.
The relative abundances and stoichiometries of the inclu-
sion complex ABZ:I-β-CD prepared by SD were determined
by mass spectrometry. The spectrum showed a molecular ion
with an m/z ratio of 1512.5, corresponding to equimolar com-
plexes between molecules of ABZ and I-β-CD with a single
substituent.
Also, no signals with an m/z ratio related to complexes
formed with I-β-CD molecules with more than one substitu-
ent or in a stoichiometric ratio other than 1:1 were observed.
This last result agrees with that obtained from the phase solu-
bility diagrams made for ABZ in the presence of I-β-CD
[33–37].
Apparent solubility and dissolution studies
Apparent solubility values of ABZ:β-CDs systems are shown
in Table 1. ABZ:β-CDs systems obtained by SD presented
higher solubility values than their respective PMs in all cases.
It should be noted that apparent solubility of ABZ:I-β-CD
systems (PM and SD) was at least 5-fold higher than the other
systems and showed statistically significant differences.
Figure 9 presents the dissolution profiles of the ABZ:I-β-
CD systems obtained by SD and PM as well as those of
Fig. 6 DSC thermograms. ABZ (a), I-β-CD (b), ABZ:I-β-CD (PM) (c),
and ABZ:I-β-CD (SD) (d)
Fig. 7 FT-IR spectrum. ABZ (a),
I-β-CD (b), ABZ:I-β-CD (PM)
(c), and ABZ:I-β-CD (SD) (d)
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similar systems formulated with ABZ and β-CD to evaluate
the efficiency of I-β-CD as a carrier. Analyzing the dissolution
profile of the ABZ:I-β-CD system obtained by SD, the max-
imum percentage of dissolved ABZ was reached 15 min after
the start of the test.
As can be seen in Table 1, dissolution parameters for
ABZ:I-β-CD (SD) were higher and statistically significant
than those percentages obtained for the analog systems pre-
pared with commercial CD derivatives, except for the system
formulated with M-β-CD.
Fig. 8 ROESY spectrum. ABZ
proton labelling (a), I-β-CD (b),
plot of the 2D ROESY spectrum
of ABZ in the presence of I-β-CD
(c, d)
Table 1 Values of apparent
solubility at 25 °C and dissolution
parameters (Q30, Q60, and DE) of
ABZ:CDs systems obtained by
PM and SD. (n = 3, ± SD)
System Solubility
(mg/mL)
Q30
(%)
Q60
(%)
DE
(%)
ABZ:β-CD PM 0.013 ± 0.002 7.7 ± 0.1 12.6 ± 0.2 16.9
ABZ:β-CD SD 0.024 ± 0.001 34.5 ± 1.9 46.6 ± 1.4 55.4
ABZ:M-β-CD PM 0.016 ± 0.001 62.9 ± 1.1 68.3 ± 1.4 70.3
ABZ:M-β-CD SD 0.069 ± 0.002 99.0 ± 2.1 94.8 ± 1.3 92.8
ABZ:HP-β-CD PM 0.011 ± 0.004 22.5 ± 0.9 31.3 ± 1.1 36.6
ABZ:HP-β-CD SD 0.048 ± 0.001 54.8 ± 2.0 65.6 ± 1.2 69.8
ABZ:I-β-CD PM 0.088 ± 0.003 13.0 ± 0.1 18.9 ± 0.8 23.4
ABZ:I-β-CD SD 0.344 ± 0.002 88.3 ± 1.1 88.4 ± 0.3 86.5
Q30 and Q60, drug released at time 30 and 60 min, respectively
DE dissolution efficiency (calculated applying Eq. 5 in an interval of time from 0 to 240 min)
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In vitro evaluation of the anthelmintic activity
of the ABZ:I-β-CD systems on T. spiralis
The effect of the formulations on the in vitro ability of ABZ to
kill adult T. spiralis worms was assessed by analysis of the
survival curves of the female parasite cultured for 48 h in
RPMI 1640 medium containing either I-β-CD, ABZ pure
drug or one of the systems (Fig. 10). I-β-CD did not affect
the viability of the cultured parasite, the median survival per-
centage at 48 h being 93.3%. Both the PM and the complex
(SD) improved ABZ parasiticidal activity, but only the com-
plex was significantly more active (ABZ vs. complex, P =
0.0086). Median survival proportions at 48 h were 88.0%
for ABZ, and 72.2% and 55.9% for the PM and the complex,
respectively.
The effect of the systems on the NL released by T. spiralis
females exposed to the antiparasitic solutions was also exam-
ined. Control and I-β-CD-treated females showed similar fe-
cundity, as assessed by the number of NL observed in each
well, thus suggesting that the modified CD has no antiparasitic
activity per se. The number of NL was affected to varying
degrees by the antiparasitic treatments. ABZ- and PM-
treated females behaved similarly, with an intermediate effect
on decreasing fecundity while treatment with the inclusion
complex was the most effective.
These results suggest that the ABZ:I-β-CD inclusion com-
plex (SD) would be a promising alternative to produce an
efficient antiparasitic pharmaceutical form of ABZ.
Conclusions
The new acidic CD derivative I-β-CD was successfully syn-
thesized. The inclusion complex was prepared and character-
ized to enhance the solubility of ABZ, a poorly soluble com-
pound with basic characteristics. The charge interaction be-
tween I-β-CD and ABZ increased its solubility by complexa-
tion. The maximum drug release was reached at 15 min, and
the inclusion complex solubility was 88-fold higher than that
of the pure drug. Also, the in vitro assay of the system’s an-
thelmintic activity showed that the complex was significantly
more effective than pure ABZ. This inclusion complex may
prove adequate to be used for oral administration since the
physicochemical considerations suggested a significant im-
provement in the solubility and the dissolution rate of the pure
drug.
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